On December 17th, the "2021 Shareholders' Meeting and Strategic Investment Signing Ceremony" of Anhui Lianchuang Biopharmaceutical Co., Ltd. was successfully held at the Hongrui Jinling Hotel in Hefei, with General Manager Wu Qihua presiding over the meeting. Shareholders' representatives attend the meeting.
At the meeting, the "2021 Work Report of the Board of Directors" was presented. The report points out that in 2021, the company will accelerate its business layout and development speed, steadily improve its supply chain management ability, have a good financial situation, make smooth progress in debt financing credit, further improve its internal control system, significantly enhance its strategic management ability, and further broaden its product pipeline, especially the development of new molecules of diabetes series products and JAK, laying a solid foundation for the future "three-year" sustainable growth plan. In 2022, the company will continue to adhere to the principle of seeking progress while maintaining stability, adhering to integrity and innovation, closely adhering to the theme of high-quality development and the goal of upgrading new research and development momentum, seizing the macro policy direction path and industry transformation strategic opportunities, continuously strengthening communication and exchange with all shareholders, actively establishing a benign and sustainable communication mechanism, and working together to create new achievements. At the same time, we answered inquiries from shareholder representatives regarding supply chain improvement, listing guidance, and the establishment of a hierarchical research and development system.
After the meeting, Anhui Lianchuang Biopharmaceutical Co., Ltd. held strategic investment signing ceremonies with Yida Capital, Chuanggu Capital, and Anhui Venture Capital respectively.